This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Diartis Pharmaceuticals, Inc.
Drug Names(s): exenatide-XTEN
Description: VRS-859 is a once monthly form of the GLP-1 analog, exenatide, which incorporates Versartis's XTEN technology. XTEN is a novel hydrophilic sequence of natural amino acids and is expressed as a fusion protein with a therapeutically active peptide or protein. Per the company, use of XTEN leads to a relatively flat PK profile and is also expected to be less immunogenic than Byetta.
Deal Structure: In December 2008, Amunix and Index Ventures entered into a 50/50-owned joint venture called Versartis. Versartis licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
In February 2011, Index Ventures and Amunix gave initial funding to Diartis Pharmaceuticals. Diartis acquired VRS-859 (exenatide-XTEN), and with this initial funding will continue its development for type 2 diabetes mellitus (T2DM).
Partners: Amunix, Inc.
Pink Sheet Weekly Trademark Review Oct. 18, 2016
Additional information available to subscribers only: